semaglutide patient education GLP1 Printable Education: Weight Loss Flyer, Editable Canva Template (digital Download) Novo Nordisk | What's the

American Association of Clinical Endocrinology Consensus Statement: Algorithm for the Evaluation and Treatment of Adults With Obesity/Adiposity-Based Chronic Disease 2025 Update

Moreover, among semaglutide-treated participants in the STEP 1 trial, 34.8% lost 20% or more of their body weight by week 68 compared to 47.06% in BARI-STEP, while 74.8% compared with 85.29% had weight loss of 10% or more, respectively

Some patients achieve A1C drops of 2 to 3 percentage points, while others see more modest improvements of 0.5 to 1 percentage point

However, their higher cost and gastrointestinal side effects may limit accessibility and long-term adherence

We'll have the same factors involved, but the way we experience it can be very different